Quantara AI launches a continuous platform designed to estimate the financial impact of cyber risk as companies move beyond periodic assessments
Updated
March 17, 2026 1:02 AM
A person tightrope walking between two cliffs. PHOTO: UNSPLASH
Cyber risk is increasingly treated as a financial issue. Boards want to know how much a cyber incident could cost the company, how it could affect earnings, and whether current security spending is justified.
Yet many organizations still measure cyber risk through periodic reviews. These assessments are often conducted once or twice a year, supported by consultants and spreadsheet models. By the time the report reaches senior leadership, the company’s systems may have changed and new threats may have emerged. The way risk is measured does not always match how quickly it evolves.
This gap is where Quantara AI is positioning its new platform. Quantara AI, a Boise-based cybersecurity startup, has introduced what it describes as the industry’s first persistent AI-powered cyber risk solution. The system is designed to run continuously rather than rely on occasional assessments.
The company’s core argument is straightforward: not every security weakness carries the same financial consequence. Instead of ranking issues only by technical severity, the platform analyzes active threats, identifies which company systems are exposed, and estimates how much money a successful attack could cost. It uses statistical models, including Value at Risk (VaR), to calculate potential losses. It also estimates how specific security improvements could reduce that projected loss.
The timing aligns with a broader market shift. International Data Corporation (IDC) projects that by 2028, 40% of enterprises will adopt AI-based cyber risk quantification platforms. These tools convert security data into financial estimates that can guide budgeting and investment decisions. The forecast reflects growing pressure on security leaders to present risk in terms that boards and regulators understand.
Traditional compliance and risk management systems often focus on meeting regulatory standards. Vulnerability management programs typically score weaknesses based on technical characteristics. Consultant-led risk studies provide detailed analysis, but they are usually performed at set intervals. In fast-changing threat environments, that model can leave decision-makers working with outdated information.
Quantara’s platform attempts to replace that periodic process with continuous measurement. It brings together threat data, internal system information and financial modeling in one system. The goal is to show, at any given time, which specific weaknesses could lead to the largest financial losses.
Cyber risk quantification as a concept is not new. What is changing is the expectation that these calculations be updated regularly and tied directly to financial decision-making. As cyber incidents carry clearer monetary consequences, companies are looking for ways to measure exposure with greater precision.
The broader question is whether enterprises will shift fully toward continuous, AI-driven risk analysis or continue relying on periodic external assessments. What is clear is that cybersecurity discussions are moving closer to financial reporting — and tools that estimate potential loss in dollar terms are becoming central to that shift.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.